evidence table
Vitamin K Bone Density Meta-Analysis Evidence Table
Structured evidence table for Vitamin K Bone Density Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin K Bone Density Meta-Analysis | 4 4 5 FHA is a state of estrogen deficiency leading to detrimental skeletal effects, including insufficient peak bone mass accrual if onset is in adolescent/early adult life, low BMD, impaired bone microarchitecture, and resultant increased fracture risk (). | 1 | Efthymiadis Agathoklis (2026) | Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials |
| Vitamin K Bone Density Meta-Analysis | Indeed, fracture risk is 2-7 times higher than in age and sex-matched healthy women (,). | 1 | Efthymiadis Agathoklis (2026) | Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials |
| Vitamin K Bone Density Meta-Analysis | transdermal 1 18 19 1 20 1 1 21 22 7 Selection of bone-directed therapy in FHA is typically guided by the outcome of non-pharmacological interventions and fracture risk. | 1 | Efthymiadis Agathoklis (2026) | Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials |
| Vitamin K Bone Density Meta-Analysis | 1 2 3 1 Functional hypothalamic amenorrhea (FHA) is a common reproductive disorder characterized by chronic anovulation due to stress, weight loss, excessive exercise, alone or in combination (). | 1 | Efthymiadis Agathoklis (2026) | Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials |
| Vitamin K Bone Density Meta-Analysis | It is characterized by low bone mass and microarchitectural deterioration of bone matrix, resulting in increased bone fragility and fracture risk [,], impacting more frequently postmenopausal women and the elderly population. | 1 | Vesa Ştefan Cristian (2026) | Association Between VKORC1 Gene Polymorphisms and Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis |
| Vitamin K Bone Density Meta-Analysis | Carboxylated OC binds hydroxyapatite crystals and contributes to bone strength and mineralization, while undercarboxylated OC, associated with vitamin K deficiency or impaired recycling, is linked to reduced BMD and increased fracture risk [,]. | 1 | Vesa Ştefan Cristian (2026) | Association Between VKORC1 Gene Polymorphisms and Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis |
| Vitamin K Bone Density Meta-Analysis | In fact, this effect is clinically relevant enough to have been included in guidelines such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing [] and the Dutch Pharmacogenetics Working Group (DPWG) []. | 1 | Vesa Ştefan Cristian (2026) | Association Between VKORC1 Gene Polymorphisms and Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis |
| Vitamin K Bone Density Meta-Analysis | 1 2 1 2 2 1 2 3 Osteoporosis is a highly prevalent disease representing a major global health problem [,]. | 1 | Vesa Ştefan Cristian (2026) | Association Between VKORC1 Gene Polymorphisms and Osteopenia and Osteoporosis: A Systematic Review and Meta-Analysis |
Source documents